<DOC>
	<DOC>NCT00996255</DOC>
	<brief_summary>The purpose of this open-label, multi center, phase I study, was to determine the safety profile of PHA-793887 administered by intravenous infusion to patients with advanced/metastatic solid tumors. This was a dose-finding study to determine the maximum tolerated dose and the dose of PHA-793887 that can be safely used in phase II investigations.</brief_summary>
	<brief_title>Dose-Escalation Study of PHA-793887 in Patients With Advanced/Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Advanced/metastatic solid tumors for which no standard therapy exists ECOG (WHO) performance status 01 Life expectancy of at least 3 months Age ≥ 18 years Adequate liver, pancreas and renal function Acceptable hematologic status Acute toxic effects from prior therapy must be resolved to NCI CTCAE Grade ≤ 1 Treatment with surgery, chemotherapy, or investigational therapy must be completed at least one month prior to treatment initiation (6 weeks for nitrosoureas or Mitomycin C and liposomal doxorubicin) Prior radiation therapy allowed in no more than 25% of bone marrow reserve Men and women of childproducing potential must agree upon the use of effective contraceptive methods In the past 6 months: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis Known brain metastases Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1 Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy Pregnant or breast feeding women Known infection with HIV, active hepatitis B or hepatitis C Patients who have exhibited allergic reactions to a similar structural compound, biological agent, or formulation History of pancreatitis or disorders making the patient at risk of pancreatitis Previous history or current presence of neurological disorders Patients with preexisting symptoms of peripheral neuropathy not related to prior anticancer therapy(ies) Concomitant treatment that may be associated with peripheral neuropathy Other severe concurrent conditions that could compromise protocol objectives.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>